UCB (company)
Search results
6 days ago · Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription… 15 May 2024 Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
GLPG Nasdaq – USD. Galapagos NV. View more. Galapagos is a global biotechnology company with operations in Europe and the US dedicated to developing transformational medicines for more years of life and quality of life.
Galapagos NV Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium Tel: +32 15 34 29 00 Fax: +32 15 34 29 01 VAT BE 0466.460.429. LinkedIn; X
Website. www .glpg .com. Galapagos NV (formerly known as Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
Find the latest Galapagos NV (GLPG) stock quote, history, news and other vital information to help you with your stock trading and investing.
About Galapagos. We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. On track to become a leading European biotech.
Read more. Financial highlights - Group net revenue, Cash position and more. A message from the management and the entire Annual Report 2021 of Galapagos NV.
Our Strategy. We are a fully integrated biotechnology company united around a single purpose: to transform patient outcomes worldwide through the relentless pursuit of life changing science and innovation for more years of life and quality of life.
Get the latest Galapagos NV (GLPG) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Dec 19, 2023 · Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the ...
